For research use only. Not for therapeutic Use.
Cinnarizine (CAT: I003032) is a multifunctional pharmaceutical compound with antihistamine and calcium channel-blocking properties. It is known to promote cerebral blood flow and has been utilized for the treatment of various neurological conditions. Cinnarizine is commonly prescribed to address cerebral apoplexy, post-trauma cerebral symptoms, and cerebral arteriosclerosis. By exerting its effects on calcium channels and histamine receptors, Cinnarizine helps regulate blood flow in the brain, potentially offering therapeutic benefits in conditions related to blood circulation and neurological function.
| Catalog Number | I003032 |
| CAS Number | 298-57-7 |
| Synonyms | 1-benzhydryl-4-cinnamylpiperazine |
| Molecular Formula | C26H28N2 |
| Purity | ≥95% |
| Target | Histamine Receptor |
| Solubility | 10 mM in DMSO |
| Storage | Store at -20°C |
| InChIKey | DERZBLKQOCDDDZ-JLHYYAGUSA-N |
| Reference | </br>1:Extrapyramidal symptoms after exposure to calcium channel blocker-flunarizine or cinnarizine. Jhang KM, Huang JY, Nfor ON, Tung YC, Ku WY, Lee CT, Liaw YP.Eur J Clin Pharmacol. 2017 Apr 6. doi: 10.1007/s00228-017-2247-x. [Epub ahead of print] PMID: 28386684 </br>2:Bioadhesive floating microsponges of cinnarizine as novel gastroretentive delivery: Capmul GMO bioadhesive coating versus acconon MC 8-2 EP/NF with intrinsic bioadhesive property. Raghuvanshi S, Pathak K.Int J Pharm Investig. 2016 Oct-Dec;6(4):181-193. doi: 10.4103/2230-973X.195923. PMID: 28123987 Free PMC Article</br>3:Influence of drug load and physical form of cinnarizine in new SNEDDS dosing regimens: in vivo and in vitro evaluations. Siqueira SD, Müllertz A, Gräeser K, Kasten G, Mu H, Rades T.AAPS J. 2017 Mar;19(2):587-594. doi: 10.1208/s12248-016-0038-4. Epub 2017 Jan 9. PMID: 28070714 </br>4:Risk of parkinsonism induced by flunarizine or cinnarizine: a population-based study. Lin HL, Lin HC, Tseng YF, Chen SC, Hsu CY.Eur J Clin Pharmacol. 2017 Mar;73(3):365-371. doi: 10.1007/s00228-016-2181-3. Epub 2016 Dec 16. PMID: 27986997 </br>5:Full spectrum and selected spectrum based chemometric methods for the simultaneous determination of Cinnarizine and Dimenhydrinate in laboratory prepared mixtures and pharmaceutical dosage form. Tawakkol SM, El-Zeiny MB, Hemdan A.Spectrochim Acta A Mol Biomol Spectrosc. 2017 Feb 15;173:892-896. doi: 10.1016/j.saa.2016.10.055. Epub 2016 Nov 1. PMID: 27837737 </br>6:In vivo evaluation of supersaturation/precipitation/re-dissolution behavior of cinnarizine, a lipophilic weak base, in the gastrointestinal tract: the key process of oral absorption. Tanaka Y, Kawakami A, Nanimatsu A, Horio M, Matsuoka J, Wada T, Kasaoka S, Yoshikawa H.Eur J Pharm Sci. 2017 Jan 1;96:464-471. doi: 10.1016/j.ejps.2016.10.023. Epub 2016 Oct 20. PMID: 27773836 </br>7:Quality by design based fabrication of Iron oxide induced mucoadhesive microspheres for enhanced bioavalibility of cinnarizine. Singh I, Rana V.Curr Drug Deliv. 2016 Oct 18. [Epub ahead of print] PMID: 27758691 </br>8:Lipid-Based Formulations Can Enable the Model Poorly Water-Soluble Weakly Basic Drug Cinnarizine To Precipitate in an Amorphous-Salt Form During In Vitro Digestion. Khan J, Rades T, Boyd BJ.Mol Pharm. 2016 Nov 7;13(11):3783-3793. Epub 2016 Sep 27. PMID: 27631273 </br>9:An investigation into the crystallization tendency/kinetics of amorphous active pharmaceutical ingredients: A case study with dipyridamole and cinnarizine. Baghel S, Cathcart H, Redington W, O/’Reilly NJ.Eur J Pharm Biopharm. 2016 Jul;104:59-71. doi: 10.1016/j.ejpb.2016.04.017. Epub 2016 Apr 21. PMID: 27108783 </br>10:Enhanced bioavailability of cinnarizine nanosuspensions by particle size engineering: Optimization and physicochemical investigations. Mishra B, Sahoo J, Dixit PK.Mater Sci Eng C Mater Biol Appl. 2016 Jun;63:62-9. doi: 10.1016/j.msec.2016.02.046. Epub 2016 Feb 19. PMID: 27040196 |
